Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Rev. Soc. Bras. Med. Trop ; 53: e20190477, 2020. tab, graf
Article in English | LILACS | ID: biblio-1057272

ABSTRACT

Abstract INTRODUCTION: Benznidazole (BZL) and Nifurtimox (NFX) are the pharmacological treatment for acute phase Chagas Disease (CD); however, therapy resistance and residual mortality development remain important unresolved issues. Posaconazole (POS) has shown a trypanocidal effect in vivo and in vitro. Thus, this study aimed at comparing the T. Cruzi parasitic load-reducing effect of the combination of BZL+POS against that of monotherapy with either, during acute phase CD, in an experimental murine model. METHODS Nineteen Wistar rats were randomly allocated to four groups and inoculated with the trypomastigotes of T. cruzi strain´s JChVcl1. The rats were administered anti-parasites from day 20-29 post-infection. The Pizzi and Brener method was used for parasitemia measurement. Longitudinal data analysis for the continuous outcome of repeated measures was performed using parasitemia as the outcome measured at days 20, 22, 24, 27, and 29 post-infection. RESULTS All four groups had similar parasitic loads (p=0.143) prior to therapy initiation. Among the three treatment groups, the BZL+POS (n=5) group showed the highest mean parasitic load reduction (p=0.000) compared with the control group. Likewise, the BZL+POS group rats showed an earlier therapeutic effect and were the only ones without parasites in their myocardial samples. CONCLUSIONS: Treatment of acute phase CD with BZL+POS was more efficacious at parasitemia and myocardial injury reduction, compared with monotherapy with either.


Subject(s)
Animals , Rats , Triazoles/administration & dosage , Trypanocidal Agents/administration & dosage , Chagas Disease/drug therapy , Parasitemia/drug therapy , Nitroimidazoles/administration & dosage , Acute Disease , DNA, Protozoan , Rats, Wistar , Disease Progression , Disease Models, Animal , Drug Therapy, Combination , Parasite Load
2.
Mem. Inst. Oswaldo Cruz ; 115: e190389, 2020. tab, graf
Article in English | LILACS | ID: biblio-1091236

ABSTRACT

BACKGROUND Chagas disease, which is caused by the protozoan Trypanosoma cruzi, is endemic to Latin America and mainly affects low-income populations. Chemotherapy is based on two nitrocompounds, but their reduced efficacy encourages the continuous search for alternative drugs. Our group has characterised the trypanocidal effect of naphthoquinones and their derivatives, with naphthoimidazoles derived from β-lapachone (N1, N2 and N3) being the most active in vitro. OBJECTIVES In the present work, the effects of N1, N2 and N3 on acutely infected mice were investigated. METHODS in vivo activity of the compounds was assessed by parasitological, biochemical, histopathological, immunophenotypical, electrocardiographic (ECG) and behavioral analyses. FINDINGS Naphthoimidazoles led to a decrease in parasitaemia (8 dpi) by reducing the number of bloodstream trypomastigotes by 25-50% but not by reducing mortality. N1 protected mice from heart injury (15 dpi) by decreasing inflammation. Bradycardia was also partially reversed after treatment with N1 and N2. Furthermore, the three compounds did not reverse hepatic and renal lesions or promote the improvement of other evaluated parameters. MAIN CONCLUSION N1 showed moderate trypanocidal and promising immunomodulatory activities, and its use in combination with benznidazole and/or anti-arrhythmic drugs as well as the efficacy of its alternative formulations must be investigated in the near future.


Subject(s)
Animals , Male , Mice , Trypanocidal Agents/therapeutic use , Naphthoquinones/therapeutic use , Chagas Disease/drug therapy , Nitroimidazoles/therapeutic use , Time Factors , Trypanocidal Agents/chemistry , Acute Disease , Naphthoquinones/chemistry , Parasitemia/drug therapy , Disease Models, Animal , Electrocardiography , Anti-Inflammatory Agents , Nitroimidazoles/chemistry
3.
Rev. Soc. Bras. Med. Trop ; 50(2): 184-193, Mar.-Apr. 2017. tab, graf
Article in English | LILACS | ID: biblio-842842

ABSTRACT

Abstract INTRODUCTION: Stimulation of inflammatory mediators such as cytokines and chemokines may cause oxidative stress in Chagas disease. In this study, we evaluated the merit of vitamins C and E as antioxidant therapy to minimize the oxidative stress-induced damage in an experimental model of Chagas disease. METHODS: Ninety-six Swiss mice were infected with Trypanosoma cruzi QM2 and treated with vitamins C, E, or both (C/E) for 60 and 120 days, and their effects compared to placebo administration were evaluated in the acute and chronic disease phases. RESULTS: There was no difference in parasitemia among treatment groups. However, histological analysis showed more severe inflammation in the skeletal muscle in the vitamin supplementation groups at both the acute and chronic phases. Biochemical analyses during the acute phase showed increased ferric-reducing ability of plasma (FRAP) and glutathione (GSH) levels in the vitamin C and C/E groups. In the chronic phase, a decrease in GSH levels was observed in the vitamin E group and a decrease in thiobarbituric acid reactive substances (TBARS) was observed in the vitamin C/E group. Moreover, there was a decrease in TBARS in the cardiac tissues of the vitamin C and C/E groups compared to that of the placebo group, although this level was greater in the vitamin E group than in the vitamin C group. CONCLUSIONS: The antioxidant action of vitamins C and E reduced oxidative stress in both the acute and chronic phases of Chagas disease, with a marked effect from joint administration, indicating their inherent synergism.


Subject(s)
Animals , Male , Ascorbic Acid/therapeutic use , Vitamin E/therapeutic use , Chagas Disease/therapy , Oxidative Stress/drug effects , Antioxidants/therapeutic use , Acute Disease , Chronic Disease , Chagas Disease/metabolism , Parasitemia/drug therapy , Disease Models, Animal , Mice
4.
Mem. Inst. Oswaldo Cruz ; 111(7): 450-453, tab
Article in English | LILACS | ID: lil-787558

ABSTRACT

Ever increasing multi-drug resistance by Plasmodium falciparum is creating new challenges in malaria chemotherapy. In the absence of licensed vaccines, treatment and prevention of malaria is heavily dependent on drugs. Potency, range of activity, safety, low cost and ease of administration are crucial issues in the design and formulation of antimalarials. We have tested three synthetic ozonides NAC89, LC50 and LCD67 in vitro and in vivo against multidrug resistant Plasmodium. In vitro, LC50 was at least 10 times more efficient inhibiting P. falciparum multidrug resistant Dd2 strain than chloroquine and mefloquine and as efficient as artemisinin (ART), artesunate and dihydroartemisinin. All three ozonides showed high efficacy in clearing parasitaemia in mice, caused by multi-drug resistant Plasmodium chabaudi strains, by subcutaneous administration, demonstrating high efficacy in vivo against ART and artesunate resistant parasites.


Subject(s)
Humans , Animals , Female , Antimalarials/pharmacology , Malaria, Falciparum/parasitology , Plasmodium falciparum/drug effects , Artemisinins/pharmacology , Chloroquine/pharmacology , Disease Models, Animal , Mefloquine/pharmacology , Mice , Parasitemia/drug therapy
5.
Mem. Inst. Oswaldo Cruz ; 110(4): 560-565, 09/06/2015. graf
Article in English | LILACS | ID: lil-748861

ABSTRACT

A rapid decrease in parasitaemia remains the major goal for new antimalarial drugs and thus, in vivo models must provide precise results concerning parasitaemia modulation. Hydroxyethylamine comprise an important group of alkanolamine compounds that exhibit pharmacological properties as proteases inhibitors that has already been proposed as a new class of antimalarial drugs. Herein, it was tested the antimalarial property of new nine different hydroxyethylamine derivatives using the green fluorescent protein (GFP)-expressing Plasmodium berghei strain. By comparing flow cytometry and microscopic analysis to evaluate parasitaemia recrudescence, it was observed that flow cytometry was a more sensitive methodology. The nine hydroxyethylamine derivatives were obtained by inserting one of the following radical in the para position: H, 4Cl, 4-Br, 4-F, 4-CH3, 4-OCH3, 4-NO2, 4-NH2 and 3-Br. The antimalarial test showed that the compound that received the methyl group (4-CH3) inhibited 70% of parasite growth. Our results suggest that GFP-transfected P. berghei is a useful tool to study the recrudescence of novel antimalarial drugs through parasitaemia examination by flow cytometry. Furthermore, it was demonstrated that the insertion of a methyl group at the para position of the sulfonamide ring appears to be critical for the antimalarial activity of this class of compounds.


Subject(s)
Animals , Mice , Rats , Antimalarials/therapeutic use , Malaria/drug therapy , Parasitemia/drug therapy , Plasmodium berghei/drug effects , Disease Models, Animal , Flow Cytometry , Green Fluorescent Proteins , In Vitro Techniques , Malaria/parasitology , Parasitemia/parasitology
6.
Mem. Inst. Oswaldo Cruz ; 109(5): 546-552, 19/08/2014. tab, graf
Article in English | LILACS | ID: lil-720416

ABSTRACT

Due to the recent advances of atovaquone, a naphthoquinone, through clinical trials as treatment for malarial infection, 19 quinone derivatives with previously reported structures were also evaluated for blood schizonticide activity against the malaria parasite Plasmodium falciparum. These compounds include 2-hydroxy-3-methylamino naphthoquinones (2-9), lapachol (10), nor-lapachol (11), iso-lapachol (12), phthiocol (13) and phenazines (12-20). Their cytotoxicities were also evaluated against human hepatoma and normal monkey kidney cell lines. Compounds 2 and 5 showed the highest activity against P. falciparum chloroquine-resistant blood-stage parasites (clone W2), indicated by their low inhibitory concentration for 50% (IC50) of parasite growth. The therapeutic potential of the active compounds was evaluated according to the selectivity index, which is a ratio of the cytotoxicity minimum lethal dose which eliminates 50% of cells and the in vitro IC50. Naphthoquinones 2 and 5, with activities similar to the reference antimalarial chloroquine, were also active against malaria in mice and suppressed parasitaemia by more than 60% in contrast to compound 11 which was inactive. Based on their in vitro and in vivo activities, compounds 2 and 5 are considered promising molecules for antimalarial treatment and warrant further study.


Subject(s)
Animals , Humans , Mice , Antimalarials/pharmacology , Malaria/drug therapy , Naphthoquinones/pharmacology , Phenazines/pharmacology , Plasmodium berghei/drug effects , Plasmodium falciparum/drug effects , Antimalarials/chemistry , Cell Line , Disease Models, Animal , Malaria/parasitology , Naphthoquinones/chemistry , Parasitic Sensitivity Tests , Parasitemia/drug therapy , Phenazines/chemistry
7.
Mem. Inst. Oswaldo Cruz ; 109(5): 540-545, 19/08/2014. tab, graf
Article in English | LILACS | ID: lil-720423

ABSTRACT

Plasmodium vivax is the most widespread parasite causing malaria, being especially prevalent in the Americas and Southeast Asia. Children are one of the most affected populations, especially in highly endemic areas. However, there are few studies evaluating the therapeutic response of infants with vivax malaria. This study retrospectively evaluated the parasitaemia clearance in children diagnosed with vivax malaria during the first five days of exclusive treatment with chloroquine (CQ). Infants aged less than six months old had a significantly slower parasitaemia clearance time compared to the group of infants and children between six months and 12 years old (Kaplan-Meier survival analysis; Wilcoxon test; p = 0.004). The impaired clearance of parasitaemia in younger children with vivax malaria is shown for the first time in Latin America. It is speculated that CQ pharmacokinetics in young children with vivax malaria is distinct, but this specific population may also allow the detection of CQ-resistant parasites during follow-up, due to the lack of previous immunity. .


Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Male , Antimalarials/therapeutic use , Chloroquine/therapeutic use , Malaria, Vivax/drug therapy , Parasitemia/drug therapy , Plasmodium vivax/drug effects , Age Factors , Antimalarials/adverse effects , Brazil , Chloroquine/adverse effects , Drug Resistance , Kaplan-Meier Estimate , Malaria, Vivax/parasitology , Parasitemia/parasitology , Retrospective Studies , Time Factors
8.
Indian J Exp Biol ; 2014 Jan; 52(1): 67-72
Article in English | IMSEAR | ID: sea-150334

ABSTRACT

The present work deals with the development of Plasmodium falciparum stages in mouse model and its potential for the study of efficacy of antimalarial drugs. C57BL/6J mice were infected with multidrug resistant P. falciparum strain then treated with arteether and artesunate. A response was observed to antimalarial drugs in terms of decrease in parasitemia. Mice infected with P. falciparum strain were successfully cured after treatment with either arteether or artesunate. The speed of parasite clearance time and burden of parasitemia differed for each drug and matched the previously reported observations, hence stressing the relevance of the model. These findings thus suggest that P. falciparum. infected human RBC (iRBC) – C57BL/6J mice can provide a valuable in vivo system and should be included in the short list of animals that can be used for the evaluation of P. falciparum responses to drugs.


Subject(s)
Animals , Artemisinins/administration & dosage , Disease Models, Animal , Drug Resistance, Multiple/genetics , Female , Humans , Malaria/drug therapy , Malaria/metabolism , Malaria/parasitology , Mice , Mice, Inbred C57BL , Parasitemia/drug therapy , Plasmodium falciparum/growth & development , Plasmodium falciparum/pathogenicity
9.
Mem. Inst. Oswaldo Cruz ; 108(7): 881-886, 1jan. 2013. tab
Article in English | LILACS | ID: lil-696010

ABSTRACT

Mice infected with Schistosoma mansoni were treated with oxamniquine, praziquantel, artesunate at the pre-patent phase, aiming at observing schistogram alterations. Half of the animals were perfused five days post-treatment for counting and classification of immature worms, based on pre-established morphological criteria (schistogram); the remaining animals were evaluated 42 or 100 days after infection and perfusion of the portal-system was performed for collection and counting of adult worms and oogram. It was observed that oxamniquine and artesunate treatment administered at the pre-postural phase causes significant reduction in the number of immature and adult worms. However, there was little reduction with praziquantel when used at the dose of 400 mg/kg for treatments administered 14, 15, 21 or 23 days post-infection. Artesunate was responsible for significant alterations in development of young worms, as well as for a higher number of worms presenting intestinal damages. Immature adult worms were detected in mice treated with artesunate or oxamniquine at the pre-patent phase of infection and recovered by perfusion 100 days after infection. Schistogram proved to be a very useful tool for experimental evaluation of the activity of antischistosomal drugs and a good model to identify the most sensitive stages to drugs.


Subject(s)
Animals , Female , Mice , Artemisinins/therapeutic use , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Schistosomicides/therapeutic use , Drug Therapy, Combination/methods , Oxamniquine/therapeutic use , Parasite Egg Count , Parasitemia/drug therapy , Praziquantel/therapeutic use , Schistosoma mansoni/growth & development
10.
Mem. Inst. Oswaldo Cruz ; 108(6): 691-698, set. 2013. graf
Article in English | LILACS | ID: lil-685486

ABSTRACT

Acute infection with Trypanosoma cruzi results in intense myocarditis, which progresses to a chronic, asymptomatic indeterminate form. The evolution toward this chronic cardiac form occurs in approximately 30% of all cases of T. cruzi infection. Suppression of delayed type hypersensitivity (DTH) has been proposed as a potential explanation of the indeterminate form. We investigated the effect of cyclophosphamide (CYCL) treatment on the regulatory mechanism of DTH and the participation of heart interstitial dendritic cells (IDCs) in this process using BALB/c mice chronically infected with T. cruzi. One group was treated with CYCL (20 mg/kg body weight) for one month. A DTH skin test was performed by intradermal injection of T. cruzi antigen (3 mg/mL) in the hind-footpad and measured the skin thickness after 24 h, 48 h and 72 h. The skin test revealed increased thickness in antigen-injected footpads, which was more evident in the mice treated with CYCL than in those mice that did not receive treatment. The thickened regions were characterised by perivascular infiltrates and areas of necrosis. Intense lesions of the myocardium were present in three/16 cases and included large areas of necrosis. Morphometric evaluation of lymphocytes showed a predominance of TCD8 cells. Heart IDCs were immunolabelled with specific antibodies (CD11b and CD11c) and T. cruzi antigens were detected using a specific anti-T. cruzi antibody. Identification of T. cruzi antigens, sequestered in these cells using specific anti-T. cruzi antibodies was done, showing a significant increase in the number of these cells in treated mice. These results indicate that IDCs participate in the regulatory mechanisms of DTH response to T. cruzi infection.


Subject(s)
Animals , Chagas Cardiomyopathy/drug therapy , Cyclophosphamide/pharmacology , Dendritic Cells/immunology , Hypersensitivity, Delayed/drug therapy , Immunosuppressive Agents/pharmacology , Trypanosoma cruzi , Antigen Presentation/immunology , Antigens, Protozoan/immunology , Chronic Disease , Chagas Cardiomyopathy/immunology , Hypersensitivity, Delayed/immunology , Mice, Inbred BALB C , Parasitemia/drug therapy , Parasitemia/immunology , Skin Tests
12.
Biomédica (Bogotá) ; 32(4): 527-535, oct.-dic. 2012. mapas, tab
Article in Spanish | LILACS | ID: lil-669100

ABSTRACT

Introducción. La determinación de la eficacia de la cloroquina contra Plasmodium vivax permite mejorar la capacidad de vigilancia de la resistencia a los antipalúdicos. Objetivo. Evaluar la eficacia terapéutica de la cloroquina como tratamiento de malaria no complicadapor P. vivax en Riberalta, Guayaramerín y Yacuiba, Bolivia. Materiales y métodos. Se llevó a cabo un estudio de la eficacia in vivo en pacientes mayores de cinco años; se suministró cloroquina (25 mg/kg en tres días) y se hizo seguimiento por 28 días, midiendo los niveles de cloroquina en sangre y desetilcloroquina, el día dos y el día de registro de reaparición de parasitemia. Para la evaluación de la incidencia acumulada de falla del tratamiento, se usó el análisis de supervivencia de Kaplan-Meier. Resultados. Se estudiaron 223 pacientes (Riberalta, 84; Guayaramerín, 80; Yacuiba, 59). Las medias de densidad parasitaria (formas asexuadas) del día 0 en Riberalta fueron de 6.147, en Guayaramerín, 4.251, y en Yacuiba, 5.214 parásitos/μl de sangre. En el mismo orden, los promedios de concentraciones sanguíneas de cloroquina-desetilcloroquina del día 2 fueron de 783, 817 y 815 ng/ml. Mientras en Yacuiba no se presentaron fracasos terapéuticos, en Riberalta ocurrieron con frecuencia de 6,2 % y en Guayaramerín de 10 %. Los valores de cloroquina y desetilcloroquina en sangre de pacientes con fracaso terapéutico fueron menores de 70 ng/ml en el día de reaparición de parasitemia. Conclusión. No se evidenció resistencia de P. vivax a la cloroquina en las tres regiones de evaluación en Bolivia. Se requieren mayores estudios de la concentración de la cloroquina en sangre.


Introduction. Knowledge of the therapeutic efficacy of chloroquine for Plasmodium vivax infections improves the capacity for surveillance of anti-malarial drug resistance. Objective. The therapeutic efficacy of chloroquine as treatment was evaluated for uncomplicated Plasmodium vivax malaria in Bolivia. Materials and methods. An in vivo efficacy study of chloroquine was undertaken in three regions of Bolivia--Riberalta, Guayaramerín and Yacuiba. Two hundred and twenty-three patients (84, 80, and 59 in the three regions, respectively) aged over 5 years old were administered with chloroquine (25 mg/kg/three days) and followed for 28 days. Blood levels of chloroquine and desethylchloroquine were measured on day 2 and on the day of reappearance of parasitemia. The cumulative incidence of treatment failure was calculated using the Kaplan and Meier survival analysis. Results. The mean parasitemias (asexual) on day 0 were 6,147 parasites/μl of blood in the Riberalta population, 4,251 in Guayaramerín and 5,214 in Yacuiba. The average blood concentrations of chloroquine-desethylchloroquine during day 2 were 783, 817, and 815 ng/ml, respectively. No treatment failures were observed in Yacuiba, whereas in Riberalta and Guayaramerín, the frequencies of treatment failures were 6.2% and 10%. Blood levels of chloroquine and desethylchloroquine in patients with treatment failure showed values below 70 ng/ml on the day of reappearance of parasitemia. Conclusion. Resistance of Plasmodium vivax to chloroquine was not demonstrated in three regions of Bolivia.


Subject(s)
Adolescent , Adult , Animals , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Pregnancy , Young Adult , Antimalarials/therapeutic use , Chloroquine/therapeutic use , Malaria, Vivax/drug therapy , Parasitemia/drug therapy , Plasmodium vivax/drug effects , Antimalarials/blood , Bolivia/epidemiology , Chloroquine/analogs & derivatives , Chloroquine/blood , Drug Resistance , Malaria, Vivax/epidemiology , Malaria, Vivax/parasitology , Parasite Load , Parasitemia/epidemiology , Parasitemia/parasitology , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/parasitology , Rural Population
13.
Biomédica (Bogotá) ; 32(4): 557-569, oct.-dic. 2012. mapas, tab
Article in Spanish | LILACS | ID: lil-669103

ABSTRACT

Introducción. Pocos estudios describen los factores asociados con la dinámica de transmisión de la malaria, o paludismo, por Plasmodium vivax en las regiones endémicas de Panamá. Objetivo. Caracterizar la dinámica de transmisión de la malaria producida por P. vivax en la región fronteriza de Panamá con Costa Rica. Materiales y métodos. Se llevó a cabo un estudio observacional, descriptivo y transversal. Se evaluaron la incidencia parasitaria anual, el índice de láminas positivas y el índice anual de exámenes de sangre. Se identificaron los anofelinos vectores, y se caracterizaron sus criaderos preferenciales, densidad larvaria e índice de picada/hombre/noche. Se hizo búsqueda pasiva y activa de casos sospechosos mediante examen de gota gruesa. Resultados. De 10.401 muestras de gota gruesa, 83 resultaron positivas para P. vivax. El 84 % de los casos provenía de zonas rurales, el 79 % constituía una población económicamente activa, la mediana de edad fue de 36 años y, la media, de 30 años. El 58,5 % de los casos fueron de sexo masculino. La incidencia parasitaria anual fue de 4,1 por 1.000 habitantes; el índice de láminas positivas fue de 0,8 % y el índice anual de exámenes de sangre fue de 51,9 %. El 65,0 % de los casos diagnosticados registró entre 100 y 2.000 parásitos/μl de sangre. Se identificaron los mosquitos vectores Anopheles albimanus y An. punctimacula. Conclusión. Es necesario el seguimiento de estudios entomológicos, el fortalecimiento de la vigilancia epidemiológica, la consideración de los factores de riesgo y la realización de un trabajo en coordinación con las autoridades de salud de Costa Rica, para controlar la malaria en esta región.


Introduction. Few studies have described the factors associated with Plasmodium vivax transmission dynamics in endemic regions from Panamá. Objective. Malaria transmission dynamics produced by P. vivax were characterized at the border between Panamá and Costa Rica. Materials and methods. In the municipality of Barú, an observational, descriptive and cross-sectional study was undertaken to measure the annual parasite index (API), slide positivity index (SPR), and the annual blood examination rate (ABER). The most frequent symptoms and signs in malaria patients were recorded. The anopheline species were identified in the area and the preferred larval habitats, the density of larval populations in the larval habitats and the bites/human/night were characterized. Results. Of a total of 10,401 thick smear blood samples, 83 were positive for P. vivax. Of these, 84% came from rural areas and 79% were from economically active individuals. The median and average ages were 36 and 30 years, respectively, and 58.5% of the malaria cases were male. API was 4.1/1,000 inhabitants; SPR was 0.8% and ABER was 51.9%. Of the diagnosed cases, 54% showed blood parasitemias ranging between 100-2,000 parasites/μl. The majority of the cases were observed in May and June. Two mosquito vector species were identified-- Anopheles albimanus and An. punctimacula. Conclusion. These observations indicate the advisibility of continued entomological studies, strengthening of epidemiological surveillance, consideration of additional risk factors and evaluation of work performance in the border region. This will require coordination with health authorities of both countries to control malaria in this region.


Subject(s)
Adolescent , Adult , Aged , Animals , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Anopheles/parasitology , Disease Outbreaks , Insect Vectors/parasitology , Malaria, Vivax/transmission , Parasitemia/transmission , Plasmodium vivax/isolation & purification , Anopheles/growth & development , Antimalarials/therapeutic use , Cross-Sectional Studies , Chloroquine/therapeutic use , Costa Rica/epidemiology , Disease Reservoirs , Incidence , Insect Bites and Stings/epidemiology , Insect Bites and Stings/parasitology , Larva , Malaria, Vivax/blood , Malaria, Vivax/drug therapy , Malaria, Vivax/epidemiology , Malaria, Vivax/parasitology , Parasite Load , Panama/epidemiology , Parasitemia/blood , Parasitemia/drug therapy , Parasitemia/epidemiology , Parasitemia/parasitology , Ponds/parasitology , Primaquine/therapeutic use , Rural Population/statistics & numerical data , Species Specificity
14.
Rev. Inst. Med. Trop. Säo Paulo ; 54(6): 319-323, Nov.-Dec. 2012. ilus, tab
Article in English | LILACS | ID: lil-656267

ABSTRACT

The tissue changes that occur in Chagas disease are related to the degree of oxidative stress and antioxidant capacity of affected tissue. Studies with vitamin C supplementation did not develop oxidative damage caused by Chagas disease in the host, but other studies cite the use of peroxiredoxins ascorbate - dependent on T. cruzi to offer protection against immune reaction. Based on these propositions, thirty "Swiss" mice were infected with T. cruzi QM1 strain and treated with two different vitamin C doses in order to study the parasitemia evolution, histopathological changes and lipid peroxidation biomarkers during the acute phase of Chagas disease. The results showed that the parasite clearance was greater in animals fed with vitamin C overdose. There were no significant differences regarding the biomarkers of lipid peroxidation and inflammatory process or the increase of myocardium in animals treated with the recommended dosage. The largest amount of parasite growth towards the end of the acute phase suggests the benefit of high doses of vitamin C for trypomastigotes. The supplementation doesn't influence the production of free radicals or the number of amastigote nests in the acute phase of Chagas disease.


As alterações teciduais que ocorrem na doença de Chagas estão relacionadas ao grau de estresse oxidativo e à capacidade antioxidante do tecido afetado. Estudos realizados com suplementação de vitamina C revelaram redução no dano oxidativo causado no hospedeiro pela doença de Chagas, porém outros estudos citam o uso de peroxiredoxinas dependentes de ascorbato pelo T. cruzi para se proteger da ação imune. Com base nessas proposições, trinta camundongos "Swiss" foram infectados com a cepa QM1 de T. cruzi e tratados com duas diferentes doses de vitamina C para estudar a evolução da parasitemia, alterações histopatológicas e dosagem de biomarcadores de peroxidação lipídica durante a fase aguda da doença de Chagas. Os resultados mostraram que a parasitemia foi maior nos animais que receberam uma superdosagem de vitamina C. Não houve diferenças significativas quanto aos biomarcadores de peroxidação lipídica e houve maior processo inflamatório no miocárdio dos animais tratados com dosagem recomendada. O maior crescimento parasitário ao fim da fase aguda sugere benefício de altas doses de vitamina C aos tripomastigotas. A suplementação não exerceu influência sobre a produção de radicais livres e o número de ninhos de amastigotas na fase aguda da doença de Chagas.


Subject(s)
Animals , Male , Mice , Antioxidants/administration & dosage , Ascorbic Acid/administration & dosage , Chagas Disease/drug therapy , Trypanosoma cruzi , Acute Disease , Chagas Disease/parasitology , Chagas Disease/pathology , Dietary Supplements , Disease Models, Animal , Dose-Response Relationship, Drug , Lipid Peroxidation , Parasitemia/drug therapy , Time Factors
15.
Rev. Soc. Bras. Med. Trop ; 45(1): 51-54, Jan.-Feb. 2012. ilus, graf, tab
Article in English | LILACS | ID: lil-614908

ABSTRACT

INTRODUCTION: To evaluate the efficacy of vitamin C in reducing the consequences generated by the production of free radicals in the acute and chronic phases of Chagas disease, two different doses of ascorbic acid were administered orally to 60 mice infected by Trypanosoma cruzi QM2 strain. METHODS: The animals were divided into six groups: G1, G2, and G3 for the acute phase study, and G'1, G'2, and G'3 for the chronic stage. The groups G1 and G'1 received 8.6x10-4mg/g of vitamin C daily, whereas G2 and G'2 received 7.14x10-3mg/g daily. The other groups, G3 and G'3, were considered placebos and received 10µL of mineral water. RESULTS: The study of the acute phase showed statistically significant differences between G1 and the other groups at various count days of the parasitemia evolution. The multiplying parasite was slower in G1 until the 11th day, but on the 22nd day it had greater parasitemia than in G2 and G3, and from the 36th day on, parasitemia stabilized at higher levels. However, when the histopathology of acute and chronic phases is considered, one does not note significant differences. CONCLUSIONS: The administration of two different doses of vitamin C was not able to protect mice and to contain the oxidative stress caused by free radicals formed by the metabolism of oxygen (reactive oxygen species) and nitrogen (reactive nitrogen species).


INTRODUÇÃO: Para avaliar a eficácia da vitamina C em reduzir as consequências geradas pela produção de readicais livres na fase aguda e crônica da doença de Chagas, duas diferentes dosagens de ácido ascórbico foram administradas oralmente para 60 camundongos infectados pela cepa QM2 de Trypanosoma cruzi. MÉTODOS: Estes animais foram divididos em seis grupos: G1, G2 e G3 para o estudo da fase aguda e G'1, G'2 e G'3 para o estudo da fase crônica. Diariamente, G1-G'1 recebeu 8.6 x 10-4 mg/g de vitamina C, G2- G'2 recebeu 7.14 x 10-3 mg/g. Os outros grupos, G3-G'3, foram considerados placebos e receberam 10µL of de água mineral. RESULTADOS: O estudo da fase aguda mostrou diferenças estatisticamente significativas entre G1 e os outros grupos em vários dias de contagens na evolução da parasitemia, e até o 11º dia a multiplicação parasitária foi menor em G1, mas no 22º dia ele tinha parasitemia maior que G2 e G3, e a partir do 36º, a parasitemia estabilizou em altos níveis. Quando considerado o histopatológico da fase aguda e crônica, não foi notado, entretanto, diferença significativa. CONCLUSÕES: Assim, foi encontrado que a administração de duas diferentes dosagens de vitamina C não foi capaz de proteger o camundongo e conter o estresse oxidativo causado pelos radicais livres formados pelo metabolismo do oxigênio (ROS) e nitrogênio (RNS).


Subject(s)
Animals , Male , Mice , Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Chagas Disease/drug therapy , Parasitemia/drug therapy , Acute Disease , Chronic Disease , Chagas Disease/pathology , Disease Models, Animal
16.
Rev. Soc. Bras. Med. Trop ; 44(6): 762-770, Nov.-Dec. 2011. tab
Article in English | LILACS | ID: lil-611759

ABSTRACT

INTRODUCTION: The co-infection Trypanosoma cruzi/HIV has been described as a clinical event of great relevance. The objective of this study wasto describe clinical and epidemiological aspects published in literature. METHODS: It is a systematic review of a descriptive nature from the databases Medline, Lilacs, SciELO, Scopus, from 1980 to 2010. RESULTS: There were 83 articles (2.8 articles/year) with a total of 291 cases. The co-infection was described in 1980 and this situation has become the defining AIDS clinical event in Brazil. This is the country with the highest number of publication (51.8 percent) followed by Argentina (27.7 percent). The majority of cases are amongst adult men (65.3 percent) native or from endemic regions with serological diagnosis in the chronic stage (97.9 percent) and indeterminate form (50.8 percent). Both diseases follow the normal course, but in 41 percent the reactivation of the Chagas disease occurs. The most severe form is the meningoencephalitis, with 100 percent of mortality without specific and early treatment of the T. cruzi. The medication of choice was the benznidazole on doses and duration normally used for the acute phase. The high parasitemia detected by direct or indirect quantitative methods indicated reactivation and its elevation is the most important predictive factor. The lower survival rate was related to the reactivation of the Chagas disease and the natural complications of both diseases. The role of the antiretroviral treatment on the co-infection cannot yet be defined by the knowledge currently existent. CONCLUSIONS: Despite the relevance of this clinical event there are still gaps to be filled.


INTRODUÇÃO: A coinfecção Trypanosoma cruzi/HIV vem sendo sistematicamente descrita como um evento clínico de grande relevância. O objetivo deste estudo foi descrever aspectos clínicos e epidemiológicos publicados na literatura científica. MÉTODOS: Trata-se de revisão sistemática, de natureza descritiva, a partir da busca nas bases Medline, Lilacs, SciELO, Scopus, de 1980 a 2010. RESULTADOS: Identificou-se 83 artigos (2,8 artigos/ano), com um total de 291 casos registrados. A coinfecção foi descrita em 1980 e, no Brasil, tornou-se evento clínico definidor de AIDS. Este é o país com maior número de publicações (51,8 por cento), seguido pela Argentina (27,7 por cento). A maioria dos casos é de homens adultos (65,3 por cento), naturais ou procedentes de regiões endêmicas, com diagnóstico sorológico, na fase crônica (97,9 por cento) e na forma indeterminada (50,8 por cento). As duas doenças evoluem naturalmente, mas em 41 por cento dos casos ocorreu reativação da doença de Chagas. A forma mais grave é a meningoencefalite, com 100 por cento de letalidade nos casos sem tratamento específico e precoce do T. cruzi. O medicamento indicado foi benznidazole, nas doses e duração utilizadas na fase aguda em imunocompetentes. O diagnóstico da reativação foi comprovado por alta parasitemia, detectada por métodos diretos ou indiretos quantitativos, sendo a sua elevação considerada fator preditivo para reativação. A menor sobrevida nacoinfecção esteve relacionada à reativação da doença de Chagas e às complicações naturais de ambas as doenças. O papel do tratamento antirretroviral sobre a evolução da coinfecção ainda não pode ser definido pelo conhecimento existente. CONCLUSÕES: Apesar da relevância deste evento clínico, ainda persistem lacunas a serem preenchidas.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Coinfection , Chagas Disease/complications , HIV Infections/complications , Acute Disease , Antiretroviral Therapy, Highly Active , Chronic Disease , Chagas Disease/drug therapy , Chagas Disease/immunology , Coinfection/drug therapy , Coinfection/immunology , HIV Infections/drug therapy , HIV Infections/immunology , Immunocompromised Host , Nitroimidazoles/therapeutic use , Parasitemia/drug therapy , Parasitemia/immunology , Trypanocidal Agents/therapeutic use
17.
Mem. Inst. Oswaldo Cruz ; 106(6): 685-690, Sept. 2011. ilus, graf
Article in English | LILACS | ID: lil-602051

ABSTRACT

The effects of artemisinin-based combination therapies (ACTs) on transmission of Plasmodium falciparum were evaluated after a policy change instituting the use of ACTs in an endemic area. P. falciparum gametocyte carriage, sex ratios and inbreeding rates were examined in 2,585 children at presentation with acute falciparum malaria during a 10-year period from 2001-2010. Asexual parasite rates were also evaluated from 2003-2010 in 10,615 children before and after the policy change. Gametocyte carriage declined significantly from 12.4 percent in 2001 to 3.6 percent in 2010 (@@χ2 for trend = 44.3, p < 0.0001), but sex ratios and inbreeding rates remained unchanged. Additionally, overall parasite rates remained unchanged before and after the policy change (47.2 percent vs. 45.4 percent), but these rates declined significantly from 2003-2010 (@@χ2 for trend 35.4, p < 0.0001). Chloroquine (CQ) and artemether-lumefantrine (AL) were used as prototype drugs before and after the policy change, respectively. AL significantly shortened the duration of male gametocyte carriage in individual patients after treatment began compared with CQ (log rank statistic = 7.92, p = 0.005). ACTs reduced the rate of gametocyte carriage in children with acute falciparum infections at presentation and shortened the duration of male gametocyte carriage after treatment. However, parasite population sex ratios, inbreeding rates and overall parasite rate were unaffected.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Antimalarials/therapeutic use , Artemisinins/therapeutic use , Chloroquine/therapeutic use , Malaria, Falciparum/drug therapy , Parasitemia/drug therapy , Plasmodium falciparum/drug effects , Drug Therapy, Combination/methods , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Nigeria , Parasitemia/parasitology , Plasmodium falciparum/growth & development , Sex Ratio
18.
West Indian med. j ; 60(1): 13-18, Jan. 2011. graf
Article in English | LILACS | ID: lil-672710

ABSTRACT

OBJECTIVES: In this study, we have examined the possibility that there is altered vascular reactivity due to the direct interaction between parasitized erythrocytes and vascular endothelial cells. METHOD: Ring preparations of rat aorta were studied using standard in vitro techniques, the rings were mounted in 20 ml organ baths containing PSS under an initial load of 1g, maintained at 37ºC atpH 7.4 and isometric contractions were recorded electronically. Rings were allowed 90 minutes to equilibrate before the commencement of the various protocols: * Dose responses to phenylephrine (PE) and other vasoactive agents (high-K+) * Acetylcholine (Ach) -induced relaxation in phenylephrine-contracted rings (pre-contraction was induced by EC70 concentration of phenylephrine) * Ach-induced relaxation in PE-precontracted, endothelium-denuded rings * Also, relaxation responses to acetylcholine was investigated through application ofa single (EC7o) concentration of acetylcholine in rings exposed to blood with varying concentrations and dilutions ofparasitized blood and varying durations ofexposure. RESULTS: Incubation with parasitized blood resulted in a significant increase in maximum contractile response to phenylephrine in the rat aortic rings (p < 0.05) but no effect to the base line. Analysis of the whole dose-response curve (using paired t-test) showed a significant left-ward shift following the addition of parasitized blood (p < 0.05), EC70 (M) values increasing from 7 x 10-7 to 5 x 10-6M. Following exposure to parasitized blood, the magnitude ofAch-induced relaxation responses reduced signi ficantlyfrom 73 ± 3.6 to 24.75 ± 7.25% in rat aortic rings (p < 0.05). Ach relaxations were significantly enhanced (p < 0.05) at 5-minute exposure; however at longer durations, Ach-relaxations were variable and inconsistent. The lesser the dilution, due to increased volume of parasitized blood, the lesser the relaxation response. Following endothelium removal, there was a marked impairment in endothelium-dependent relaxation responses to ACh in both the control and incubated vessels. Exposure to parasitized blood did not significantly alter contractile responses induced by potassium depolarization. CONCLUSIONS: This gives evidence in support of an endothelium-dependent action of malaria parasites as vascular effects ofmalaria parasites are mediated, at least in part, via endothelium-dependent mechanism(s).


OBJETIVO: En este estudio, hemos examinado la posibilidad de que exista una reactividad vascular alterada debido a la interacción directa entre los eritrocitos parasitados y las células endoteliales vasculares. MÉTODO: Se estudiaron preparaciones de anillo de aorta de rata usando técnicas in vitro estándar. Los anillos fueron montados en baños de órgano de 20 ml que contenían solución salina fisiológica (SSF) con una carga inicial de 1g, mantenida a 37ºC con un pH de 7.4, y las contracciones isométricas fueron registradas electrónicamente. A los anillos se les dio un tiempo de 90 minutos para permitir que se equilibraran, antes del comienzo de los varios protocolos. * Respuestas a la dosis de fenilefrina (FE) y otros agentes vasoactivos (K+ alto) * Relajación inducida mediante acetilcolina (Ac) en los anillos contraídos con fenilefrina (la precontracción fue inducida mediante una concentración EC70 de fenilefrina) * Relajación inducida mediante Ac en anillos despojados de endotelio. Pre-contraídos con FE. * También, se investigaron las respuestas de relajación a la acetilcolina a través de la aplicación de una sola concentración (EC70) de acetilcolina en anillos expuestos a la sangre con diversas concentraciones y diluciones de sangre parasitada y distintas duraciones de exposición. RESULTADOS: La incubación con sangre parasitada tuvo como resultado un aumento significativo en la respuesta contráctil máxima a la fenilefrina en los anillos aórticos de las ratas (p < 0.05) pero ningún efecto a la línea de base. El análisis de toda la curva de respuesta a la dosis (usando la prueba t pareada) mostró un desplazamiento significativo hacia la izquierda tras la adición de sangre parasitada (p < 0.05), EC70 (M), aumentado los valores de 7 x 10-7 a 5 x 10-6M. Tras la exposición a la sangre parasitada, la magnitud de las respuestas a la relajación inducida por Ac se redujo significativamente de 73 ± 3.6 a 24.75 ± 7.25% en los anillos aórticos de ratas (p < 0.05). Las relajaciones por Ac mejoraron significativamente (p < 0.05) a los 5 minutos de exposición. Sin embargo, a duraciones más largas, las relajaciones por Ac fueron variables e inconstantes. Mientras menor era la dilución, debido al aumento de volumen de la sangre parasitada, menor era la respuesta de relajación. Una vez retirado el endotelio, se producía un marcado deterioro en las respuestas de relajación dependiente del endotelio, ante el Ac, tanto en los recipientes de control como en los encubados. La exposición a la sangre parasitada no alteró de manera significativa las respuestas contráctiles inducidas por la despolarización del potasio. CONCLUSIONES: Esto provee evidencias en apoyo a una acción dependiente del epitelio, por parte de los parásitos de la malaria, por cuanto los efectos vasculares de los parásitos de la malaria se hallan mediados, al menos en parte, por los mecanismos dependientes del endotelio.


Subject(s)
Animals , Rats , Aorta/parasitology , Endothelium, Vascular/cytology , Endothelium, Vascular/parasitology , Erythrocytes/parasitology , Malaria, Falciparum/drug therapy , Acetylcholine/pharmacology , Disease Models, Animal , Parasitemia/drug therapy , Phenylephrine/pharmacology
19.
Mem. Inst. Oswaldo Cruz ; 105(2): 233-238, Mar. 2010. ilus
Article in English | LILACS | ID: lil-544632

ABSTRACT

Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Although the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.


Subject(s)
Animals , Female , Male , Mice , Chagas Disease/drug therapy , Parasitemia/drug therapy , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi/drug effects , Acute Disease , Chronic Disease , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Trypanocidal Agents/toxicity
20.
Article in English | IMSEAR | ID: sea-139103

ABSTRACT

Background. Lymphatic filariasis is a major vector-borne parasitic disease. The global programme to eliminate lymphatic filariasis was launched in 1997 and currently over 570 million people are covered under it in 48 countries. Mass annual single-dose drug administration of diethylcarbamazine (DEC), co-administrated with albendazole for 5–6 years and mass distribution of diethylcarbamazine-fortified salt are the two strategies for elimination of filariasis. Methods. Asymptomatic volunteers residing in Puducherry, India were screened for microfilaria (mf) by examining nocturnal thick blood smears. Those testing positive were randomly assigned to receive a single dose of DEC (6 mg/kg body weight) or albendazole 400 mg or both. Participants were hospitalized for 5 days. Membrane filtration count was used to assess microfilaraemia and ELISA (Og4C3) assay to measure circulating filarial antigens (CFA). Measurements were done before treatment and at 1, 2 and 3 years post-treatment. Viability of the adult worms was assessed by looking for the filarial dance sign (FDS) using ultrasound examination of the scrotum in men with hydrocele. Results. Fifty-four microfilaraemic individuals were studied. The mf prevalence started decreasing only by day 180 posttreatment in the DEC group but much earlier in the other two groups (day 30 in the albendazole and day 90 in the DEC with albendazole group). The decrease in mf was marginal (17.6%, 26.3% and 27.8%, respectively) by the end of year 1 posttreatment, but significant (96.7%, 78.6% and 93.3%, respectively) by the end of year 2 post-treatment (p<0.05). By the end of year 3, the level decreased to 80% in the DEC, 90% in the albendazole and to 100% in the DEC and albendazole groups. However, the mf intensity decreased © The National Medical Journal of India 2010 Vector Control Research Centre, Department of Health Research (ICMR), Indira Nagar, Puducherry 605006, India S. L. HOTI, S. P. PANI, P. VANAMAIL, K. ATHISAYA MARY, L. K. DAS, P. K. DAS Correspondence to S. L. HOTI; slhoti@yahoo.com significantly (by 39%; p<0.05) by day 7 post-treatment in both the DEC and DEC with albendazole groups, but only by day 30 in the albendazole group. In all the drug groups, the prevalence as well as intensity of CFA returned to pretreatment levels by the end of year 3 post-treatment. Conclusion. Annual single-dose administration of all the 3 drug regimens significantly reduced antigenaemia levels. There were no significant differences in the efficacy and overall pattern of CFA clearance between the 3 drug regimens.


Subject(s)
Adolescent , Adult , Albendazole/administration & dosage , Albendazole/therapeutic use , Animals , Anthelmintics/therapeutic use , Antigens, Helminth/blood , Carrier State/drug therapy , Child , Diethylcarbamazine/administration & dosage , Diethylcarbamazine/therapeutic use , Female , Filariasis/drug therapy , Humans , Male , Microfilariae/drug effects , Middle Aged , Parasitemia/drug therapy , Wuchereria bancrofti/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL